share_log

Biora Therapeutics | SCHEDULE 13G: Others

Biora Therapeutics | SCHEDULE 13G: Others

Biora Therapeutics | SCHEDULE 13G：其他
SEC announcement ·  03/21 06:33
牛牛AI助理已提取核心訊息
On March 12, 2024, Biora Therapeutics, Inc. was the subject of a Schedule 13G filing with the SEC, indicating a significant acquisition of shares by several entities and individuals. Context Capital Management, LLC, along with Michael S. Rosen, William D. Fertig, Charles E. Carnegie, and Context Partners Master Fund, L.P., reported shared voting and dispositive power over 2,989,698 shares of Biora Therapeutics' common stock, representing 0.9% of the class. The filing clarified that these parties are not forming a group and each disclaims beneficial ownership of the securities except to the extent of their pecuniary interest. The shares in question are issuable upon conversion of Convertible Senior Notes due 2028, subject to a 9.9% ownership limitation. The reported percentage ownership is based on 27,209,277 shares of Biora Therapeutics' common stock outstanding as of December 20, 2023. The filing was completed on March 20, 2024, with all parties certifying that the acquisition of shares is in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
On March 12, 2024, Biora Therapeutics, Inc. was the subject of a Schedule 13G filing with the SEC, indicating a significant acquisition of shares by several entities and individuals. Context Capital Management, LLC, along with Michael S. Rosen, William D. Fertig, Charles E. Carnegie, and Context Partners Master Fund, L.P., reported shared voting and dispositive power over 2,989,698 shares of Biora Therapeutics' common stock, representing 0.9% of the class. The filing clarified that these parties are not forming a group and each disclaims beneficial ownership of the securities except to the extent of their pecuniary interest. The shares in question are issuable upon conversion of Convertible Senior Notes due 2028, subject to a 9.9% ownership limitation. The reported percentage ownership is based on 27,209,277 shares of Biora Therapeutics' common stock outstanding as of December 20, 2023. The filing was completed on March 20, 2024, with all parties certifying that the acquisition of shares is in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
2024年3月12日，Biora Therapeutics, Inc.成爲向美國證券交易委員會提交的附表13G文件的主體，這表明多個實體和個人對股票進行了重大收購。Context Capital Management, LLC以及邁克爾·羅森、威廉·費蒂格、查爾斯·卡內基和Context Partners萬事達基金有限責任公司報告了對佔該類別0.9％的Biora Therapeutics普通股的2,989,698股共享投票權和處置權。該文件澄清說，這些當事方沒有組成一個團體，除非其金錢利益，否則均否認對證券的實益所有權。有關股票可在轉換2028年到期的可轉換優先票據後發行，但所有權限制爲9.9％。報告的所有權百分比基於截至2023年12月20日的Biora Therapeutics已發行普通股的27,209,277股。該文件已於2024年3月20日完成，所有各方均證明收購股票是在正常業務過程中進行的，不是爲了改變或影響發行人的控制權。
2024年3月12日，Biora Therapeutics, Inc.成爲向美國證券交易委員會提交的附表13G文件的主體，這表明多個實體和個人對股票進行了重大收購。Context Capital Management, LLC以及邁克爾·羅森、威廉·費蒂格、查爾斯·卡內基和Context Partners萬事達基金有限責任公司報告了對佔該類別0.9％的Biora Therapeutics普通股的2,989,698股共享投票權和處置權。該文件澄清說，這些當事方沒有組成一個團體，除非其金錢利益，否則均否認對證券的實益所有權。有關股票可在轉換2028年到期的可轉換優先票據後發行，但所有權限制爲9.9％。報告的所有權百分比基於截至2023年12月20日的Biora Therapeutics已發行普通股的27,209,277股。該文件已於2024年3月20日完成，所有各方均證明收購股票是在正常業務過程中進行的，不是爲了改變或影響發行人的控制權。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。